Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
G Strassmann, M Fong, JS Kenney… - The Journal of clinical …, 1992 - Am Soc Clin Investig
The Journal of clinical investigation, 1992•Am Soc Clin Investig
In this report we describe an experimental model of cachexia that fulfills the criteria of an
early effect with a small tumor mass not related to the growth rate of the tumor, and
progressive wasting of muscle and fat without a detectable loss of appetite. C-26. IVX is a
cell line derived from murine colon-26 adenocarcinoma which retains the transplantability of
the original tumor and induces true cachexia in syngeneic hosts. Evidence is presented to
support a role for interleukin (IL-6) as a cachectic factor in the development of cancer …
early effect with a small tumor mass not related to the growth rate of the tumor, and
progressive wasting of muscle and fat without a detectable loss of appetite. C-26. IVX is a
cell line derived from murine colon-26 adenocarcinoma which retains the transplantability of
the original tumor and induces true cachexia in syngeneic hosts. Evidence is presented to
support a role for interleukin (IL-6) as a cachectic factor in the development of cancer …
In this report we describe an experimental model of cachexia that fulfills the criteria of an early effect with a small tumor mass not related to the growth rate of the tumor, and progressive wasting of muscle and fat without a detectable loss of appetite. C-26.IVX is a cell line derived from murine colon-26 adenocarcinoma which retains the transplantability of the original tumor and induces true cachexia in syngeneic hosts. Evidence is presented to support a role for interleukin (IL-6) as a cachectic factor in the development of cancer cachexia in this model system. Thus, increasing levels of IL-6 in C-26.IVX-bearing mice correlate with the development of cachexia. If the primary tumors were resected, mice gained weight and the levels of IL-6 in the serum were reduced significantly. Moreover, monoclonal antibody to murine IL-6 (but not anti-tumor necrosis factor antibody) was able to significantly suppress the development of key parameters of cachexia in tumor bearing mice.
The Journal of Clinical Investigation